共查询到18条相似文献,搜索用时 328 毫秒
1.
目的研究观察支架术后双抗血小板治疗对老年冠心病病人血小板聚集率、血栓事件的影响。方法本次研究所选取的患者都是在2017年2月至2018年2月这段期间在我院和烟台毓璜顶医院进行诊断与治疗的冠心病老年病患,选取在此期间收治的120例冠心病病患者进行探究。将患者随机组合后分为2组,对照组60例采用的双抗血小板治疗方法为口服阿司匹林片与氯吡格雷片,观察组60例病患采用双抗治疗的方法为口服阿司匹林片与替格瑞洛片。两组患者均采用进口支架。观察病患血小板聚集情况及主要心血管事件(MACE)发生情况及出血情况。结果观察组双抗治疗的60例病患的血小板聚集率低于对照组的血小板聚集率,P0.05。治疗期间内均未出现严重出血事件,凝血三项(凝血酶原时间PT、活化的部分凝血酶时间aPTT、凝血酶时间TT)的六个月内的检查结果无显著差异。观察组MACE的发生率明显低于对照组,对比结果差异显著。结论支架术后采用双抗血小板治疗老年冠心病,病人血小板聚集率降低、血栓事件发生也显著降低,值得临床推广应用。 相似文献
2.
目的:探讨经皮冠状动脉介入治疗(PCI)术后标准双抗血小板和长期双抗血小板对冠心病患者预后的影响。方法:回顾性分析2015年1月-2017年12月在上级医院行PCI术后回本院复诊的冠心病患者200例的临床资料,按治疗方法不同将其分为观察组和对照组,各100例。观察组给予长期双抗血小板治疗,对照组给予标准双抗血小板治疗。比较两组治疗前后的血小板聚集率、红细胞计数、血小板计数以及有效性终点事件和安全性终点事件发生率。结果:治疗前及治疗3、6、12个月,两组血小板聚集率、红细胞计数、血小板计数比较,差异均无统计学意义(P0.05);治疗18、24个月,两组红细胞计数比较差异均无统计学意义(P0.05),但观察组血小板聚集率、血小板计数均低于对照组,比较差异均有统计学意义(P0.05);观察组主要及次要有效性终点事件发生率均低于对照组,比较差异均有统计学意义(P0.05);两组大出血、小出血及安全性终点事件总发生率比较,差异均无统计学意义(P0.05)。结论:PCI术后使用长期双抗血小板治疗可安全有效地抑制血小板聚集,减少冠心病患者术后心血管不良事件的发生率。 相似文献
3.
[摘要] 目的 探讨根除幽门螺杆菌( helicobacterpylori , H . pylori )在经皮冠状动脉支架植入术( percutaneous
coronaryinterventions , PCI )后双联抗血小板治疗中的价值。方法 将 282 例合并 H . pylori 感染的 PCI 后患者随
机分为 A 、 B 、 C3 组, 125 例无 H . pylori 感染的 PCI 后患者作为对照组, 4 组均给予双重抗血小板治疗, B 组同时给
予泮托拉唑半年治疗、 C 组同时给予根除 H . pylori 联合泮托拉唑半年治疗,比较各组消化不良症状、上消化道出
血( uppergastrointestinalhemorrhage ,
UGH )及主要不良心血管事件( majoradversecardiovascularevents , MACE )
发生率。结果 消化不良发生率比较, A 组 > 对照组 >B 组 >C 组(
48.9% vs 29.8% vs 19.1% vs 7.5% , P <
0.05 ); UGH 发生率比较, A 组 > 对照组、 B 组 >C 组( 16.0% vs 6.5% 、 7.4% vs 1.1% , P <0.05 ),对照组和 B 组
比较差异无统计学意义( P >0.05 );
4 组 MACE 发生率比较差异均无统计学意义( P >0.05 )。 H . pylori 根除失败
患者 UGH 发生率与根除成功患者比较差异无统计学意义( 6.67% vs 0% , P >0.05 ))。结论 H . pylori 感染可增
加 PCI 后双重抗血小板治疗患者 1 年内消化不良症状和 UGH 的发生;含泮托拉唑的根除 H . pylori 方案联合半
年的泮托拉唑维持治疗可有效预防和减少上述症状,且不增加患者 MACE 的发生。但能否通过上述治疗减少
MACE 的发生需要大样本、长程观察。 相似文献
4.
目的比较冠状动脉支架术(PCI)后国产氯吡格雷与进口氯吡格雷抗血小板治疗的安全性和有效性。方法收集2008年7月至2010年7月在滨州市中心医院行冠状动脉支架术患者132例,随机分为A组(国产氯吡格雷组,n=64)及B组(进口氯吡格雷组,n=68)。两组患者均采用标准阿司匹林、氯吡格雷联合抗血小板治疗至少1年。研究主要终点为随访1年时的心源性死亡、非致死性心肌梗死(MI)、脑卒中发生率。次要终点为随访1年时的因不良反应停药率。结果两组临床基线资料差异无统计学意义(P〉0.05)。随访1年时,A组心源性死亡、非致死性Ml、脑卒中发生率(分别为1.6%、1.6%、0%)与B组(分别为1.5%、2.9%、0%)比较,差异无统计学意义(P〉0.05)。A组出血事件发生率为3.1%,与B组1.5%比较,差异亦无统计学意义(P=0.284)。结论国产氯吡格雷与进口氯吡格雷均可有效地减少PCI术后主要终点及次要终点事件的发生率。 相似文献
5.
《河南医学研究》2018,(5)
目的分析国产雷帕霉素洗脱支架置入治疗无保护左主干严重狭窄冠心病的临床效果。方法选取2014年8月至2015年9月北京大学人民医院收治的33例无保护左主干病变冠心病患者,按随机数表法分为A组(16例)和B组(17例)。A组接受国产雷帕霉素洗脱支架置入治疗,B组接受进口雷帕霉素洗脱支架置入治疗,对比分析两组置入支架数、直径、长度、术后心脏不良事件及支架内再狭窄发生情况。结果两组置入支架数、直径、长度比较,差异无统计学意义(P均>0.05)。两组术后均未发生急/亚急性支架血栓、心肌再梗死、死亡等心脏不良事件。A组2例(12.5%)发生支架内再狭窄,B组2例(11.8%)发生支架内再狭窄,A组和B组支架内再狭窄发生率比较,差异无统计学意义(P>0.05)。结论采用国产雷帕霉素洗脱支架置入治疗无保护左主干严重狭窄冠心病安全有效,值得临床推广应用。 相似文献
6.
目的 探讨急性心肌梗死(AMI)应用双联抗血小板联合质子泵抑制剂(PPI)治疗对患者预后的影响.方法 选择原广州军区总医院心内科及我院综合内科于2014年1月至2016年6月期间收治的468例AMI患者为研究对象,根据随机数表法分为A、B、C三组,每组156例,所有患者均接受经皮冠状动脉介入(PCI)支架置入治疗,术后接受阿司匹林+氯吡格雷双联抗血小板治疗,A组不应用PPI,B组应用奥美拉唑,C组应用埃索美拉唑治疗,疗程6个月.比较治疗后三组患者主要不良心血管事件(MACE)、上消化道出血及支架内血栓形成情况.结果 A、B、C三组患者的MACE及支架内血栓形成发生率分别为9.63%和1.92%、15.38%和5.13%、13.46%和3.21%,两两比较差异均无统计学意义(P>0.05);B组和C组上消化道出血的发生率分别为3.85%和1.92%,明显低于A组的9.63%,差异均有统计学意义(P<0.05).结论 PCI术后双联抗血小板治疗过程中,加用奥美拉唑或埃索美拉唑均可有效预防上消化道出血的发生,且不增加心血管事件的发生风险. 相似文献
7.
目的分析心肌梗死患者经皮冠状动脉介入术(PCI)后双抗血小板治疗变替格瑞洛单抗治疗的可行性。方法 2013年6月至2015年6月共收集90例心肌梗死患者为研究对象,依据随机数字表格法将患者分为两组各45例,均行PCI治疗,术后均给予阿司匹林+替格瑞洛双联抗血小板治疗,对照组双抗用药1年,观察组双抗6个月后开始慢慢减少阿司匹林应用,3个月后完全变替格瑞洛单抗治疗,共用药1年,比较2组治疗前后凝血指标、血小板聚集率、不良心血管事件及出血事件。结果与治疗前比较,2组治疗1年PT、aPTT明显延长,血小板聚集率明显下降,差异有统计学意义(P0.05);2组不良心血管事件及出血事件比较差异无统计学意义(P0.05)。结论心肌梗死患者PCI术后阿司匹林+替格瑞洛双联抗血小板治疗6个月变替格瑞洛单抗用药至1年相比双联1年在抑制血小板聚集方面作用类似,但变替格瑞洛单抗治疗能有效减少出血发生,且不显著增加不良心血管事件。 相似文献
8.
李静 《世界核心医学期刊文摘》2019,(45)
目的研究冠状动脉钙化(CAC)患者PCI术后不同双抗血小板方案治疗对血小板高反应(HPR)及心血管事件(MACE)的影响。方法纳入2016年10月至2018年2月于我院行PCI治疗的CAC患者148例,依据随机数字表法分别将所有CAC患者纳入实验组(n=74)与对照组(n=74),对照组PCI术前、术后均给予阿司匹林+氯吡格雷治疗,实验组PCI术前、术后均给予阿司匹林+替格瑞洛治疗。观察2组患者PCI术后3 d血小板活化复合物(PAC-1)、P-选择素(CD62P)、血小板最大聚集率(MPAR),PCI术后3d HPR发生情况,PCI术后90d内MACE发生情况,治疗期内药物不良反应等指标。结果 PCI术后3 d,实验组PAC-1、CD62P、MPAR均小于对照组(P 0.05)。PCI术后3 d,实验组HPR发生率为16.22%(12/74)低于对照组39.19%(29/74)(P0.05)。PCI术后90d内,实验组MACE发生率12.16%低于对照组28.38%(P0.05)。治疗期内,实验组轻微出血发生率(8.11%)、少量出血发生率(1.35%)、呼吸困难发生率(2.70%)与对照组轻微出血发生率(1.35%)、少量出血发生率(0.00%)、呼吸困难发生率(0.00%)差异无统计学意义(P 0.05)。结论 CAC患者PCI术后阿司匹林+替格瑞洛治疗方案可有效减少HPR及MACE发生率,安全可靠。 相似文献
9.
目的比较氯吡格雷、阿司匹林单用及双联抗血小板长期治疗对老年冠心病患者经皮冠状动脉介入术(PCI)术后的影响。方法选择我院2012年3月~2015年3月收治96例老年冠心病且行PCI术治疗患者作为研究对象,随机分为A、B、C三组。A组应用阿司匹林行单抗血小板治疗,B组应用氯吡格雷,C组联合阿司匹林与氯吡格雷行双联抗血小板治疗,比较两组治疗前后凝血指标、心血管不良事件发生率、药物不良反应发生率。结果三组经长期抗血小板治疗后,凝血指标PT、a PTT均获得改善,组内前后差异有统计学意义(P0.05);组间比较上,三组治疗前的比较均无统计学意义(P0.05),治疗后,C组PT、a PTT均高于A组与B组,差异有统计学意义(P0.05)。A组与B组心血管不良事件发生率均为18.8%(6/32),高于C组3.1%(1/32),差异均有统计学意义(P0.05)。A、B、C三组药物不良反应发生率分别为15.6%(5/32)、12.5%(4/32)、15.6%(5/32),两两比较均无统计学意义(P0.05)。结论老年冠心病患者PCI术后长期予以氯吡格雷、阿司匹林联合抗血小板治疗额有效预防血小板聚集,大幅降低心血管事件发生率,与单抗方案相比预后更佳,安全性高。 相似文献
10.
紫杉醇洗脱支架在冠状动脉病变介入治疗的远期疗效和安全性 总被引:4,自引:0,他引:4
目的 评价紫杉醇洗脱支架治疗冠状动脉病变的远期临床疗效和安全性.方法 118例(共有187处病变)入选本研究的患者随机分为2组,紫杉醇洗脱支架组59例,裸支架对照组59例.结合冠脉造影结果和心电图或者心肌ECT等显像结果确定冠脉靶血管来植入支架,紫杉醇洗脱支架组患者冠脉96处病变,共植入支架96枚,裸支架对照组患者冠脉91处病变,共植入支架91枚.术后患者随访2年,观察心脏主要不良事件(MACE)事件的发生率,复查平板运动试验以及冠状动脉造影.结果 两组基本临床特征相似,支架植入成功率为100%.有95%的患者完成了2年的随访,紫杉醇洗脱支架组总的MACE事件发生率为5.1%(3/59),裸支架对照组为23.7%(13/59),两组比较差异有显著性(P<0.05);紫杉醇洗脱支架组5.2%(5/96)靶血管发生了支架内再狭窄,裸支架对照组15.4%(14/91)靶血管发生了支架内再狭窄,相比紫杉醇洗脱支架组发生率高(P<0.05).两组患者在出血事件发生率方面相比差异无显著性(P>0.05).结论 紫杉醇洗脱支架在预防再狭窄及降低MACE方面有优势,治疗冠状动脉病变安全性与裸支架相同. 相似文献
11.
目的 探讨在椎动脉支架置入术后患者的CYP2C19基因型分布与椎动脉支架内再发狭窄、复发性卒中和出血等预后不良事件的关系。 方法 回顾性分析205例接受CYP2C19基因检测的椎动脉狭窄并行支架置入术患者的临床资料。根据CYP2C19基因型所致肝脏对药物代谢情况,将椎动脉支架置入术后患者分为快、中、慢代谢3组,观察预后。 结果 3组患者在接受氯吡格雷及阿司匹林双联抗血小板治疗前,血小板抑制率未达标(ADP%<50%)的患者数量比较,差别无统计学意义(P>0.05); 接受氯吡格雷及阿司匹林双联抗血小板治疗6月后,差别有统计学意义(P<0.05)。3组患者在椎动脉支架置入术后规律氯吡格雷及阿司匹林双联抗血小板治疗6月内椎动脉支架内再狭窄和复发性脑梗死患者数量比较,差别有统计学意义(P<0.05),但对于其常见副作用如颅内出血及胃肠道、牙龈等其他部位出血的患者数量比较,差别无统计学意义(P>0.05)。 结论 在椎动脉支架置入术后患者中,CYP2C19基因快代谢型使用氯吡格雷及阿司匹林双联抗血小板治疗预防椎动脉支架内再狭窄、复发性脑梗死的获益明显优于中代谢型和慢代谢型,且颅内出血及胃肠道、牙龈等其他部位出血影响不明显。在椎动脉支架置入术后常规使用氯吡格雷及阿司匹林双联抗血小板治疗的患者中,CYP2C19基因多态性为影响患者椎动脉支架内再狭窄和复发性脑梗死的重要危险因素。 相似文献
12.
目的观察不同随访模式对冠心病支架置入术后抗血小板治疗依从性及1年再入院率的影响。方法选取2011年5月至2014年5月连续3年在我院心内科成功接收PCI手术并置于支架的256例老年冠心病患者为研究对象,随机分为对照组和观察组,对照组患者接受定期门诊随访调查,观察组在对照组基础上同时进行定时电话随访调查,随访时间为1年。两组患者随访结束后,对两组患者采用调查问卷对随访效果进行评估,比较两组患者PCI术后1年内抗血小板药物服用依从性。比较两组患者PCI后不良心血管事件(MACE)发生情况,比较两组患者并发症发生情况、生活质量评分和1年内再入院率。结果 PCI术后1年内随访调查发现,观察组中患者医嘱依从性明显高于对照组(P0.05)。观察组患者的抗血小板知识、及时就诊、按时复诊及自我管理评分均明显高于对照组(P0.05)。术后1年内随访观察组靶血管重建、累积MACE发生率和再次入院发生率明显低于对照组,(P0.05)。经术后1年随访观察组患者生活质量评分高于对照组(P0.05)。结论定期门诊随访联合电话随访能够提高患者冠心病支架置入术后抗血小板药物服用的依从性和降低1年再入院率,对患者术后生活质量起到积极作用。 相似文献
13.
Wang CH Fang Q Zhang SY Shen ZJ Fan ZJ Jin XF Zeng Y Liu ZY Xie HZ Yang M 《中华医学杂志(英文版)》2012,125(16):2803-2806
Background The long-term safety and efficacy of drug-eluting stents (DES) versus bare metal stents (BMS) are unclear and controversial issues in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study was to compare the long-term outcome of STEMI patients undergoing primary PCI with DES versus BMS implantation.
Methods A total of 191 patients with acute STEMI undergoing PCI from Jan. 2005 to Dec. 2007 were enrolled. Patients received DES (n=83) or BMS (n=108) implantation in the infarction related artery according to physician’s discretion. The primary outcome was the occurrence of major adverse cardiac events (MACE), which was defined as a composite of death, myocardial infarction (MI), target vessel revascularization (TVR) and stent thrombosis. The difference of MACE was observed between DES and BMS groups.
Results The clinical follow-up duration was 3 years ((41.7±16.1) months). MACE occurred in 20 patients during three years follow-up. Logistic regression analysis showed that the left ventricular ejection fraction (LVEF) was an independent predictor for MACE in the follow-up period (P=0.0301). There was no significant difference in all-cause mortality (3.61% vs. 7.41%, P=0.2647), the incidence of myocardial infarction (0 vs. 0.93%, P=0.379) and stent thrombosis (1.20% vs. 1.85%, P=0.727) between the DES group and BMS group. The incidence of MACE was significantly lower in the DES group compared to the BMS group (4.82% vs. 14.81%, P=0.0253). The rate of TVR was also lower in the DES group (0 vs. 5.56%, P=0.029). In the DES group, there was no significant difference in the incidence of MACE between sirolimus eluting stents (SES, n=73) and paclitaxel-eluting stents (PES, n=10) subgroups (2.74% vs. 20.00%, P >0.05).
Conclusions This finding suggested that drug-eluting stents significantly reduced the need for revascularization in patients with acute STEMI, without increasing the incidence of death or myocardial infarction. Use of DES significantly decreased the incidence of MACE compared with BMS during the 3-year follow-up. 相似文献
14.
目的:观察非心脏手术对已安装冠脉内药物涂层支架患者预后的影响。方法:收集2007年1月~2009年12月安装冠脉内药物涂层支架后接受过非心脏手术的患者60例,其中27例患者在安装支架后12个月内手术(A组),33例在安装支架后12个月后手术(B组)。另外,随机选择安装冠脉内药物涂层支架,但其后未接受过手术的患者30例作为对照(C组)。观察术后1年内(A组和B组)或安装支架后1年内(C组)主要不良心脑血管事件(MACCE)的发生情况。结果:A组的MACCE发生率显著高于C组(P〈0.05),B组与C组的MACCE发生率差异无统计学意义(P〉0.05)。结论:在安装冠脉内药物涂层支架后的双抗期接受非心脏手术严重影响患者预后,非急诊手术宜在双重抗凝的12个月以后进行。 相似文献
15.
ZHANG Lei QIAO Bing HAN Ya-ling LI Yi XU Kai ZHANG Quan-yu YANG Li-xia 《中华医学杂志(英文版)》2013,126(6):1039-1045
Background The gender difference on long-term outcome in unselected patients after percutaneous coronary intervention (PCI) has not yet been fully investigated.This study aimed to evaluate the gender d... 相似文献
16.
Incidence of thrombosis after implantation of drug-eluting stents in patients with coronary artery disease 总被引:1,自引:0,他引:1
CHEN Ji-lin YANG Yue-jin GAO Li-jian HUANG Jing-han QIN Xue-wen QIAO Shu-bin XU Bo YAO Min LIU Hai-bo WU Yong-jian YUAN Jin-qing CHEN Jue YOU Shi-jie DAI Jun LI Jian-jun GAO Run-lin 《中华医学杂志(英文版)》2008,121(21):2144-2147
Background Randomized clinical trials have demonstrated equivalent safety to bare-metal stents after drug-eluting stents (DES) implantation. However, the DES thrombosis in randomized trials could not be comparable to those observed in clinical practice, frequently including off-label indications. This study sought to assess the incidence of DES thrombosis after implantation of DES in patients with real world coronary artery disease (CAD) in China.
Methods From December 2001 to April 2007, 8190 consecutive patients received the treatment with DES, 5412 patients completed one year follow-up: 2210 with sirolimus-eluting stent Cypher, 1238 with paclitaxel-eluting stent Taxus and 1964 with Chinese sirolimus-eluting stent Firebird, After two years of follow-up, there were 2176 patients (1245 Cypher, 558 Taxus and 373 Firebird). All patients were treated with aspirin and clopidogrel over at least 9 months.
Results Among 8190 patients, 17 patients had acute stent thrombosis (0.24%): 7 in the Cypher group, 4 Taxus and 6 Firebird; 23 patients had subacute stent thrombosis: 8 Cypher, 6 Taxus and 9 Firebird. The incidence of acute and subacute thrombosis was 0.49%: 0.50% Cypher, 0.63% Taxus and 0.41% Firebird. The incidence of late thrombosis at one year followup was 0.63%: 0.63% Cypher, 0.88% Taxus and 0.46% Firebird; at two year follow-up the incidence was 0.74%: 0.72% Cypher, 0.90% Taxus and 0.54% Firebird. There was no significant difference among three groups at 1 year and 2 years follow-up.
Conclusion The first generation DES in the treatment of complex lesions are safe and effective if patients are aggressively treated with dual antiplatelet agents. 相似文献
Methods From December 2001 to April 2007, 8190 consecutive patients received the treatment with DES, 5412 patients completed one year follow-up: 2210 with sirolimus-eluting stent Cypher, 1238 with paclitaxel-eluting stent Taxus and 1964 with Chinese sirolimus-eluting stent Firebird, After two years of follow-up, there were 2176 patients (1245 Cypher, 558 Taxus and 373 Firebird). All patients were treated with aspirin and clopidogrel over at least 9 months.
Results Among 8190 patients, 17 patients had acute stent thrombosis (0.24%): 7 in the Cypher group, 4 Taxus and 6 Firebird; 23 patients had subacute stent thrombosis: 8 Cypher, 6 Taxus and 9 Firebird. The incidence of acute and subacute thrombosis was 0.49%: 0.50% Cypher, 0.63% Taxus and 0.41% Firebird. The incidence of late thrombosis at one year followup was 0.63%: 0.63% Cypher, 0.88% Taxus and 0.46% Firebird; at two year follow-up the incidence was 0.74%: 0.72% Cypher, 0.90% Taxus and 0.54% Firebird. There was no significant difference among three groups at 1 year and 2 years follow-up.
Conclusion The first generation DES in the treatment of complex lesions are safe and effective if patients are aggressively treated with dual antiplatelet agents. 相似文献
17.
Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction 总被引:1,自引:0,他引:1
Background There are few evidences about the value of drug eluting stent in patients with ST-segment elevation myocardial infarction (STEMI). We prospectively designed a randomized controlled trial to compare the safety and efficacy of Firebird sirolimus eluting stent (Firebird stent) and bare metal stent (BMS).
Methods Patients with STEMI enrolled during one year period were randomized to undergo implantation of Firebird stent or BMS, and clinical and angiographic follow-up. The primary endpoint of the present study was in-lesion late lumen loss (LLL) at 6 months, and secondary endpoint includes stent thrombosis and major adverse cardiac events (MACE) at 6 months.
Results During one year period, 156 patients were randomized into the Firebird stent group (101 patients with an average age of 57.8 years) or the BMS group (55 patients with 59.7 years on average). Six-month angiographic follow-up was available in 66.3% and 63.7% of patients assigned to Firebird stent and BMS, respectively. At 6-month follow-up, mortality, target vessel revascularization (TVR) and MACE were 2.0%, 6.9% and 9.9% in the Firebird stent group, while 3.6%, 30.9% and 36.4% in the BMS group (P〈0.05). Subacute thrombosis occurred in 1 patient in both groups, respectively. The mean LLL was 0.18 mm in the Firebird stent group versus 0.72 mm in the BMS group.
Conclusion Implantation of Firebird sirolimus eluting stent for STEMI may greatly reduce TVR and MACE at 6 months with low incidence of acute/subacute stent thrombosis compared with BMS. 相似文献
18.
Zhang RY Zhang Q Zhu JZ Chen LL Zhang CY Zhou XC Yuan Y Zhong ZX Li L Qiu J Wang W Chen XM Yang ZJ Yan JC Chen SL Hou YQ Wu YQ Luo HM Qiu JP Zhu L Wang Y Fu GS Wang JA Ma KH Yin YH Zhang DF Hu XS Zhu GY Shen WF;Safety Efficacy Registry of Yinyi stent 《中华医学杂志(英文版)》2011,124(21):3521-3526
BackgroundPolymer coating on coronary stents induces vascular inflammatory response,reduces re-endothelialization,and affects long-term outcome after percutaneous coronary intervention (PCI).The SERY-1 registry aimed to determine whether a novel polymer-free paclitaxel-eluting microporous Yinyi stent could improve 1-year outcome after index procedure in real-world clinical practice.Methods Clinical and angiographic data and follow-up outcome were collected in 1045 patients who underwent PCI with implantation of ≥1 Yinyi stents between June 2008 and August 2009 at 27 medical centers.The primary endpoint was the cumulative rate of composite major adverse cardiac events (MACE) and the secondary endpoint was the incidence of stent thrombosis at 1 year.Results Overall,1376 lesions were treated successfully with 1713 Yinyi stents,and 1019 (98.7%) patients received dual antiplatelet therapy for at least 12 months.During 1-year follow-up,8 patients (0.78%) had cardiac death,6 (0.58%)suffered non-fatal myocardial infarction,and 46 (4.46%) underwent repeat PCI due to recurrence of angina,resulting in 1-year MACE-free survival of 94.09%.Stent thrombosis occurred in 10 (0.97%) patients,and the rate of Academic Research Consortium (ARC) definite or probable stent thrombosis was 0.78%.Conclusions Polymer-free paclitaxel-eluting microporous Yinyi stent is effective and safe for interventional treatment of coronary artery disease in real-world clinical practice,without recourse to carrier polymer.Potential long-term clinical advantages of this stent deserve further investigation. 相似文献